Jun 16, 2022Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem SiteAlpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended...
Jun 8, 2022FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCCJERUSALEM, June 8, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
Jun 8, 2022Alpha Tau Announces Resignation of Gary Leibler from its Board of DirectorsJERUSALEM, June 7, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
May 26, 2022Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds-...
May 24, 2022First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer TrialJERUSALEM, May 23, 2022 -- Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW), the developer of the pioneering alpha-radiation cancer...